Search Results

SetPoint Medical Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle Advisory Program Pilot from the U.S. Food and Drug Administration for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis.

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis.

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.

SetPoint Medical today announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies.

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the enrollment of the first participant in Stage 2 of the company’s RESET-RA pivotal study.